Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. - Wikidata - wikimedia - TriplyDB

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.

http://www.wikidata.org/entity/Q43797374

about

Anaplastic lymphoma kinase: signalling in development and disease Combined surgical and molecular therapy: the gastrointestinal stromal tumor model Spontaneous rupture of giant gastric stromal tumor into gastric lumen Implications of growth factor alterations in the treatment of pancreatic cancer Surgical resection for gastrointestinal stromal tumors (GIST): experience on 25 patients Targeting gastrointestinal stromal tumors: the role of regorafenib Current Chemotherapy and Potential New Targets in Uterine Leiomyosarcoma Pharmacology and rationale for imatinib in the treatment of scleroderma The GIST of targeted therapy for malignant melanoma Moving molecular targeted drug therapy towards personalized medicine: issues related to clinical trial design KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size.A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential.Unveiling changes in the landscape of patient populations in cancer early drug development Metastatic duodenal GIST: role of surgery combined with imatinib mesylate Identification of cancer genes by mutational profiling of tumor genomes Current management and prognostic features for gastrointestinal stromal tumor (GIST)Steered molecular dynamics simulations reveal the likelier dissociation pathway of imatinib from its targeting kinases c-Kit and Abl Activity and side effects of imatinib in patients with gastrointestinal stromal tumors: data from a German multicenter trial.Malignant peripheral nerve sheath tumor in neurobifromatosis type-1: two case reports.Small molecule kinase inhibitors approved by the FDA from 2000 to 2011: a systematic review of preclinical ADME data.Phase II trial of gemcitabine in advanced sarcomas.Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumors Gastrointestinal stromal tumor.Outcomes of first-line chemotherapy in patients with advanced or metastatic leiomyosarcoma of uterine and non-uterine origin Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial.Gastrointestinal stromal tumor and its targeted therapeutics.Computational analysis of the binding specificity of Gleevec to Abl, c-Kit, Lck, and c-Src tyrosine kinases.High density DNA array analysis reveals distinct genomic profiles in a subset of gastrointestinal stromal tumors Amplification of chromosomal segment 4q12 in non-small cell lung cancer Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients.Upper gastrointestinal bleeding due to gastric stromal tumour: a case report.Evaluation of self-reported progression and correlation of imatinib dose to survival in patients with metastatic gastrointestinal stromal tumors: an open cohort study Targeted therapy for cancer: the gastrointestinal stromal tumor model.Assessing tumor vascularization as a potential biomarker of imatinib resistance in gastrointestinal stromal tumors by dynamic contrast-enhanced magnetic resonance imaging.Practical management of patients with chronic myeloid leukemia.NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.Dramatic regression and bleeding of a duodenal GIST during preoperative imatinib therapy: case report and review.Frequent KIT mutations in human gastrointestinal stromal tumors.Expression of c-kit receptor in human cholangiocarcinoma and in vivo treatment with imatinib mesilate in chimeric mice The kinase inhibitor imatinib mesylate inhibits TNF-{alpha} production in vitro and prevents TNF-dependent acute hepatic inflammation

P2860

Q24312329-4110595C-2570-4093-AF5B-3D8AF4C8E3F2 Q24675987-252F8A6E-AC5D-4692-9FD0-C10BC3BD3405 Q24793072-AC488A00-E2ED-40B0-80B1-861BECC1D282 Q24800145-F0C923A3-06F9-4298-A38C-BE1B51E4A375 Q25256659-6711477A-BD15-4A1C-8F63-BB34DE5D7081 Q26747162-0F805D11-D2D9-4DBD-AD7B-255F17FD163F Q26767435-42265CA6-D49E-49E0-B23D-DF29F63D1245 Q26825153-A45DB471-535B-42E1-A969-47368B5E9F4F Q26827092-27543983-2880-4195-873A-457D245A14F1 Q26830525-47DEABA2-ECC8-4F30-891D-BEF139CDEF89 Q27824783-FC26DEA3-9999-4BE7-AC54-2E0EB145FB65 Q27824814-40C9D958-C8B6-4FAF-B870-A88E91FB089A Q28073826-0C25F1FB-3F86-4A0B-A292-AE093AA508A2 Q28221725-948F0998-888E-41F1-8A40-363DB7B25C1E Q28239452-31CE9763-69A7-4A5F-BB14-76BC0882A797 Q28391684-99EE8D58-172C-4D20-8896-4996B67AB729 Q28472368-7A617864-8468-452D-B3D4-06A80CD1932D Q30485073-DF810297-9158-49F1-98F8-5613199E0A4D Q30485989-1D11A53D-FCE2-40B6-AFAB-45F129074B71 Q30664269-23DF84CC-2A98-4A43-B5E5-8D0C1028F2C9 Q33343208-5EB20352-EE69-451F-81A1-C7D1C6B48D12 Q33391125-206D6D35-DF01-4600-9EB4-29DF1275C678 Q33489084-47AD501F-09AA-4894-9588-7971652760D0 Q33523297-FF1361DA-937E-4E1B-831C-327962E070DF Q33561602-D317F8FC-279A-47FC-A119-200B9F47F41A Q33579642-496D9451-C749-43F4-805A-CF5BA4AACB98 Q33631185-797BDB9C-13D8-4549-B429-B15319E87EAC Q33695315-8AB02C18-43CF-4C08-B2EE-AC0E928D4400 Q33708516-1FA97F5D-26D5-467C-913A-5852D62F5C6D Q33710999-4248298A-FC4F-4B6E-8294-A3640D794C47 Q33718435-DCAE9BCA-ECF9-45A0-9FAA-0FC111684087 Q33756542-5802E5C1-CD28-4351-B28A-100A06F6CF66 Q33807742-7C396F11-4FFE-4FF2-8589-447F8517415C Q33840444-8A3320D1-0F4B-4A27-B511-601FEAB2356B Q33849146-97E7755E-5277-43C1-8B01-72D41BC8AB92 Q33921067-DE09EE37-849E-4F59-807F-D7DCFD931AE3 Q33931063-D653385D-507A-4CFD-8417-F5CE82D476F7 Q33985734-B0FB681A-2026-4E1A-B68D-512581DE382A Q34012590-FFB225E4-A33B-446C-8FD1-AAA363C1B658 Q34015801-77DC5384-4636-49D3-A391-564BADA8E4AC

P2860

Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.

http://www.wikidata.org/entity/Q43797374

description

2001 nî lūn-bûn

@nan

2001年の論文

@ja

2001年学术文章

@wuu

2001年学术文章

@zh

2001年学术文章

@zh-cn

2001年学术文章

@zh-hans

2001年学术文章

@zh-my

2001年学术文章

@zh-sg

2001年學術文章

@yue

2001年學術文章

@zh-hant

name

Safety and efficacy of imatini ...... omal tumours: a phase I study.

@en

Safety and efficacy of imatinib

@nl

type

label

Safety and efficacy of imatini ...... omal tumours: a phase I study.

@en

Safety and efficacy of imatinib

@nl

prefLabel

Safety and efficacy of imatini ...... omal tumours: a phase I study.

@en

Safety and efficacy of imatinib

@nl

P1433

Q43797374-119303F8-F864-4375-91BB-47C1097E3D07

P1476

Q43797374-F22F4815-0D48-4035-B51C-9BF6B1B59B20

P2093

Q43797374-11C1C7B2-F6DC-45BB-95AC-15EE906A4576

Q43797374-1986B1EA-C87F-4D93-B990-AEC950E1B874

Q43797374-385BB617-2E7F-437E-A5F1-3A3F02F10E69

Q43797374-41DEC92B-E954-4C43-9C7E-5ADD88BBB898

Q43797374-44C22586-9AAA-4E1B-BCF1-AF5EE11B5144

Q43797374-4E2B2E27-0391-46E3-AF77-49004A1A0744

Q43797374-958B1786-D1DC-49A1-A0D9-D64DD03A0986

Q43797374-A13727C3-622E-40D0-A8FB-E07943530034

Q43797374-A2381878-5B98-41C8-9DE7-F71E9D18EA23

Q43797374-D3470701-A6E8-4D8F-919F-F9EED2C26F77

P304

Q43797374-0C66C8B4-E30F-4A3C-A591-F12788ABB356

P31

Q43797374-7484FF25-B7A8-4A9A-9266-72B6EE57B2B0

P356

Q43797374-903CCABD-9E9A-4F2D-9628-D46F77CEA3E6

P407

Q43797374-ADFF1823-662A-4B65-9B66-0E81F22614E4

P433

Q43797374-A9338B3D-DA71-4C9B-A70C-76105B8BDF58

P478

Q43797374-8658B8AD-6DF2-4B0A-AFBD-A68335F73E33

P577

Q43797374-76133FB3-5756-4B35-89FC-E27C42EB73B5

P698

Q43797374-3710D4ED-0A0F-49FA-8717-4121E7B862D5

P356

S0140-6736(01)06535-7

P1433

P1476

Safety and efficacy of imatini ...... omal tumours: a phase I study.

@en

P2093

A T van Oosterom

http://www.w3.org/2001/XMLSchema#string

A Webb

http://www.w3.org/2001/XMLSchema#string

E Donato di Paola

http://www.w3.org/2001/XMLSchema#string

European Organisation for Rese ...... Tissue and Bone Sarcoma Group

http://www.w3.org/2001/XMLSchema#string

I Judson

http://www.w3.org/2001/XMLSchema#string

J Verweij

http://www.w3.org/2001/XMLSchema#string

M Martens

http://www.w3.org/2001/XMLSchema#string

M Van Glabbeke

http://www.w3.org/2001/XMLSchema#string

O S Nielsen

http://www.w3.org/2001/XMLSchema#string

R Sciot

http://www.w3.org/2001/XMLSchema#string

P304

1421-1423

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0140-6736(01)06535-7

http://www.w3.org/2001/XMLSchema#string

P407

P433

9291

http://www.w3.org/2001/XMLSchema#string

P478

358

http://www.w3.org/2001/XMLSchema#string

P577

2001-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11705489

http://www.w3.org/2001/XMLSchema#string